Results 151 to 160 of about 4,259,087 (330)
KMT2A-rearranged acute lymphoblastic leukemia (ALL) is characterized by deregulation of the epigenome and shows susceptibility towards histone deacetylase (HDAC) inhibition.
Tamara C. A. I. Verbeek +7 more
doaj +1 more source
Molecular Glue Degraders in Early Development for Cancer Therapy
ABSTRACT Molecular glue degraders are an emerging class of small molecule allosteric modulators that induce or stabilize protein‐protein interactions, enabling targeted degradation of previously intractable proteins. By redirecting E3 ligases to recognize neosubstrates, proteins that are not typically recognized by a specific E3 ubiquitin ligase, they ...
E. Sila Ozdemir +4 more
wiley +1 more source
AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo +4 more
wiley +1 more source
The potential of HDAC inhibitors as cognitive enhancers [PDF]
Histone acetylation is a prominent epigenetic modification of the central nervous system that is unequivocally associated with an increase in the rate of gene transcription.
Gräff, Johannes, Tsai, Li-Huei
core +1 more source
Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi +5 more
wiley +1 more source
Synthesis, Characterization and Reactivities of New HDAC Inhibitors
The advancement of tumors and growing resistance to existing anticancer drugs required the constant need for new drugs and/or therapies. Histone deacetylase (HDAC) is found to be overexpressed in some cancer cells, which condenses the chromatin ...
Shao, Dan, Zheng, Jenny
core
The epigenetic landscape of plant defense: Unlocking nature's toolkit for new plant protection
This review examines how epigenetic mechanisms regulate plant immune gene activation, repression, and priming, then links these natural regulatory layers to emerging epigenetic editing, discussing their potential for precise, heritable crop protection and the challenges.
Xuexia Liu, Zhenhui Zhong
wiley +1 more source
Pan-HDAC Inhibitors Promote Tau Aggregation by Increasing the Level of Acetylated Tau
Epigenetic remodeling via histone acetylation has become a popular therapeutic strategy to treat Alzheimer’s disease (AD). In particular, histone deacetylase (HDAC) inhibitors including M344 and SAHA have been elucidated to be new drug candidates ...
Soo Hyun Lee +6 more
core +1 more source
Epigenetic Regulation of Liver Fibrosis: Mechanisms and Therapeutic Implications
This review synthesizes the epigenetic mechanisms—DNA methylation, histone modifications, and non‐coding RNAs—that drive hepatic stellate cell activation and the progression of liver fibrosis. It further evaluates emerging therapeutic strategies targeting these epigenetic regulators, including DNA methyltransferase and histone deacetylase inhibitors ...
Maryam Jadid Tavaf +8 more
wiley +1 more source
Although histone deacetylase (HDAC) inhibitors have demonstrated significant advantages in the field of targeted cancer therapy, numerous adverse events have been observed due to the high doses required to achieve therapeutic effects.
Yanran Liu +6 more
doaj +1 more source

